Scarica l'app Stockscreener
5.23
4.81%
0.24
Pre-mercato:
5.10
-0.13
-2.49%
Precedente Chiudi:
$4.99
Aprire:
$5.39
Volume 24 ore:
130.48K
Relative Volume:
0.01
Capitalizzazione di mercato:
$9.48M
Reddito:
-
Utile/perdita netta:
$-37.75M
Rapporto P/E:
-1.6092
EPS:
-3.25
Flusso di cassa netto:
$-30.91M
1 W Prestazione:
+5.02%
1M Prestazione:
+1,692%
6M Prestazione:
+2,005%
1 anno Prestazione:
+107.54%
Intervallo 1D:
$5.089
$5.45
Intervallo di 1 settimana:
$4.74
$5.45
Portata 52W:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Nome
Cellectar Biosciences Inc
Settore
Industria
Telefono
(608) 441-8120
Indirizzo
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Confronta CLRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
5.23 | 14.23M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Ripresa | Ladenburg Thalmann | Buy |
| 2020-07-01 | Iniziato | Oppenheimer | Outperform |
| 2020-01-21 | Ripresa | ROTH Capital | Buy |
| 2019-09-13 | Iniziato | ROTH Capital | Buy |
| 2016-12-21 | Iniziato | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
What analysts say about Cellectar Biosciences Inc. stockSuperior portfolio returns - jammulinksnews.com
Cellectar Biosciences Inc. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
Is Cellectar Biosciences Inc. a good long term investmentConsistently exceptional gains - Autocar Professional
What drives Cellectar Biosciences Inc. stock pricePhenomenal returns - jammulinksnews.com
Cellectar’s Cancer Therapy Hopes Face A Cash Crunch - Finimize
What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - Yahoo Finance
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser
How Cellectar Biosciences Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences shares rise 3.59% premarket after closing $6.9 million public offering. - AInvest
Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener
Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Quiver Quantitative
Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire
Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus
Cellectar Biosciences prices $6 million public offering - Investing.com
Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative
Cellectar Biosciences prices $6 million public offering By Investing.com - Investing.com Canada
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World
Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener
Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com
Cellectar and Nusano sign multi-year radioisotope supply agreement By Investing.com - Investing.com India
Cellectar Biosciences enacts one-for-thirty reverse stock split on Nasdaq - Investing.com
Cellectar Biosciences (CLRB) Submits Study Protocol to FDA for P - GuruFocus
Cellectar Biosciences Trading Halted: News Pending - AInvest
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire
Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India
Cellectar reports improved survival in pediatric brain tumor trial - Investing.com
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - The Manila Times
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | CLRB Stock News - GuruFocus
Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan
Cellectar Biosciences Inc Azioni (CLRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):